1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Philippines Pharmaceuticals and Healthcare Report Q1 2017

Philippines Pharmaceuticals and Healthcare Report Q1 2017

  • November 2016
  • -
  • Business Monitor International
  • -
  • 98 pages

Includes 3 FREE quarterly updates


BMI View:

Despite high enrolment numbers with the Philippine Health Insurance Corporation (PhilHealth), further reforms to the Philippines's healthcare system will be necessary for the country's universal healthcare scheme to galvanise the pharmaceutical and healthcare sector. Factors such as a lack of human resources, poor patient accessibility to clinics and hospitals and limited insurance coverage will all hold back growth in the healthcare sector.

Headline Expenditure Projections



- Pharmaceuticals: PHP150.44bn (USD3.33bn) in 2015, rising to PHP156.19bn (USD3.26bn) in 2016; +3.8% in local currency terms and -2.1% in US dollar terms. Forecast unchanged from last quarter.

- Healthcare: PHP656.11bn (USD14.52bn) in 2015, rising to PHP722.32bn (USD15.06bn) in 2016; +10.1% in local currency terms and +3.8% in US dollar terms. Forecast unchanged from last quarter. Risk/Reward Index The Philippines is ranked in 14th place out of the 20 pharmaceutical markets assessed in Asia Pacific (scoring 45.0 out of 100), trailing the regional average in all subsectors. In Q117, Japan remains by far the most attractive market in the Asia Pacific region (scoring 80.6), followed by Australia (66.0).

Table Of Contents

Philippines Pharmaceuticals and Healthcare Report Q1 2017
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Philippines 2014-2020) 7
SWOT 10
Industry Forecast 12
Pharmaceutical Market Forecast 12
Table: Pharmaceutical Sales, Historical Data And Forecasts (Philippines 2012-2020) 15
Healthcare Market Forecast 16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Philippines 2012-2020) 19
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Philippines 2012-2020) 19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Philippines 2012-2020) 20
Prescription Drug Market Forecast 21
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Philippines 2012-2020) 23
Patented Drug Market Forecast 24
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Philippines 2012-2020) 26
Generic Drug Market Forecast 27
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Philippines 2012-2020) 29
OTC Medicine Market Forecast 30
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Philippines 2012-2020) 32
Pharmaceutical Trade Forecast 33
Table: Pharmaceutical Trade Data And Forecasts (Philippines 2014-2020) 35
Table: Pharmaceutical Trade Data And Forecasts Local Currency (Philippines 2014-2020) 35
Industry Risk/Reward Index 36
Asia Pacific Risk/Reward Index 36
Philippines Risk/Reward Index 42
Rewards 42
Risks 43
Regulatory Review 44
Intellectual Property Issues 48
Pricing Regime 51
Reimbursement Regime 55
Market Overview 56
Healthcare Sector 57
Table: Healthcare Resources (Philippines 2010-2015) 60
Table: Healthcare Personnel (Philippines 2010-2015) 60
Table: Healthcare Activity (Philippines 2010-2015) 61
Health Insurance 61
Clinical Trials 67
Epidemiology 68
Competitive Landscape 70
Research-Based Industry 70
Table: Multinational Market Activity 70
Generic Drugmakers 71
Pharmaceutical Distribution 73
Pharmaceutical Retail Sector 75
Table: Overview Of BnB, BNB and P100 Programme 78
Table: Cost Of Generic Drugs In Philippines (PHP) 78
Table: Number Of BnBs And BNBs In Selected Philippine Regions 79
Company Profile 80
GlaxoSmithKline Philippines 80
Novartis 83
Demographic Forecast 87
Table: Population Headline Indicators (Philippines 1990-2025) 88
Table: Key Population Ratios (Philippines 1990-2025) 88
Table: Urban/Rural Population and Life Expectancy (Philippines 1990-2025) 89
Table: Population By Age Group (Philippines 1990-2025) 89
Table: Population By Age Group % (Philippines 1990-2025) 90
Glossary 92
Methodology 94
Pharmaceutical Expenditure Forecast Model 94
Healthcare Expenditure Forecast Model 94
Notes On Methodology 95
Risk/Reward Index Methodology 96
Index Overview 97
Table: Pharmaceutical Risk/Reward Index Indicators 97
Indicator Weightings 98

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.